Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
talquetamab + daratumumab
- Development stage
- Phase 3
- Lead developer
- Johnson & Johnson
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous
01
Overview
The combination of **talquetamab** (a GPRC5D-directed bispecific T-cell engager) and daratumumab (an anti-CD38 monoclonal antibody) is an investigational regimen evaluated primarily in relapsed/refractory multiple myeloma. Talquetamab works by redirecting T cells to malignant plasma cells via binding to GPRC5D and CD3, forming an immune synapse and inducing cytotoxicity. Daratumumab targets CD38, leading to direct cancer cell death, antibody-dependent cell-mediated cytotoxicity, and immune modulation. The rationale for combination is based on both drugs acting on different antigens on myeloma cells, enhancing antitumor activity and potentially depleting regulatory T-cells that may otherwise dampen the immune response[2][3][5][6].
- Other names
- talquetamab plus daratumumab
02
Targets
CD38 (Cluster of Differentiation 38)CD3 (T-cell surface glycoprotein CD3)GPRC5D
Beyond the preview
Go deeper on talquetamab + daratumumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on talquetamab + daratumumab.